These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10672828)

  • 1. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus.
    Nilsson J; Skobe V; Johansson J; Willén R; Johnsson F
    Scand J Gastroenterol; 2000 Jan; 35(1):10-6. PubMed ID: 10672828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus.
    Fortun PJ; Anagnostopoulos GK; Kaye P; James M; Foley S; Samuel S; Shonde A; Badreldin R; Campbell E; Hawkey CJ; Ragunath K
    Aliment Pharmacol Ther; 2006 Mar; 23(6):735-42. PubMed ID: 16556175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk.
    Kelty CJ; Gough MD; Van Wyk Q; Stephenson TJ; Ackroyd R
    Scand J Gastroenterol; 2007 Nov; 42(11):1271-4. PubMed ID: 17852872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer risk in Barrett's oesophagus.
    Dias Pereira A; Suspiro A; Chaves P
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progression from intestinal metaplasia to adenocarcinoma in Barrett s esophagus: usefulness of endoscopic surveillance].
    Burdiles P; Csendes A; Smok G; Braghetto I; Korn O
    Rev Med Chil; 2003 Jun; 131(6):587-96. PubMed ID: 12942585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett's adenocarcinoma.
    Goda K; Tajiri H; Ikegami M; Urashima M; Nakayoshi T; Kaise M
    Gastrointest Endosc; 2007 Jan; 65(1):36-46. PubMed ID: 17185078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barrett's oesophagus: results from a 13-year surveillance programme.
    Bani-Hani K; Sue-Ling H; Johnston D; Axon AT; Martin IG
    Eur J Gastroenterol Hepatol; 2000 Jun; 12(6):649-54. PubMed ID: 10912484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus.
    Gatenby PA; Ramus JR; Caygill CP; Shepherd NA; Watson A
    Scand J Gastroenterol; 2008; 43(5):524-30. PubMed ID: 18415743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
    Quera R; O'Sullivan K; Quigley EM
    Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Barrett carcinoma--diagnosis, screening, surveillance, endoscopic treatment, prevention].
    Peitz U; Malfertheiner P
    Z Gastroenterol; 2007 Dec; 45(12):1264-72. PubMed ID: 18080229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
    Incarbone R; Bonavina L; Bassi F; Peracchia A
    Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
    Cooper BT; Chapman W; Neumann CS; Gearty JC
    Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of clinico-pathological changes in Barrett oesophagus.
    Punia RS; Arya S; Mohan H; Duseja A; Bal A
    J Assoc Physicians India; 2006 Mar; 54():187-9. PubMed ID: 16800342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale for screening and surveillance of Barrett's metaplasia.
    Wani S; Sharma P
    Best Pract Res Clin Gastroenterol; 2006; 20(5):829-42. PubMed ID: 16997164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
    Conio M; Blanchi S; Lapertosa G; Ferraris R; Sablich R; Marchi S; D'Onofrio V; Lacchin T; Iaquinto G; Missale G; Ravelli P; Cestari R; Benedetti G; Macrì G; Fiocca R; Munizzi F; Filiberti R
    Am J Gastroenterol; 2003 Sep; 98(9):1931-9. PubMed ID: 14499768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.